Advances in treatment of hyperkalemia in chronic kidney disease

Bibliography

• Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169(12):1156-62
   PubMed Web of Science ®Google Scholar
• Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012;109(10):1510-13
   PubMed Web of Science ®Google Scholar
• Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol 2014;10(11):653-62
   PubMed Web of Science ®Google Scholar
• Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 2014;34(3):333-9
   PubMed Web of Science ®Google Scholar
• Takaichi K, Takemoto F, Ubara Y, Mori Y. Analysis of factors causing hyperkalemia. Intern Med 2007;46(12):823-9
   PubMed Web of Science ®Google Scholar
• Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 2010;5(3):531-48
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007;49(1):12-26
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Ruilope LM. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int 2014;85(3):536-46
   PubMed Web of Science ®Google Scholar
• McGowan CE, Saha S, Chu G, et al. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J 2009;102(5):493-7
   PubMed Web of Science ®Google Scholar
• Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010;21(5):733-5
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014;312(21):2223-33
   PubMed Web of Science ®Google Scholar
• Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015;372(3):222-31
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372(3):211-21
   PubMed Web of Science ®Google Scholar
• Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium reduction over 52 weeks in hyperkalemic patients with diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015;314(2):151-61
   PubMed Web of Science ®Google Scholar
• Welling PA. Regulation of potassium channel trafficking in the distal nephron. Curr Opin Nephrol Hypertens 2013;22(5):559-65
   PubMed Web of Science ®Google Scholar
• Welling PA. Regulation of renal potassium secretion: molecular mechanisms. Semin Nephrol 2013;33(3):215-28
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980;17(1):118-34
   PubMed Web of Science ®Google Scholar
• Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351(6):585-92
   PubMed Web of Science ®Google Scholar
• Simmons DH, Avedon M. Acid-base alterations and plasma potassium concentration. Am J Physiol 1959;197:319-26
   PubMed Web of Science ®Google Scholar
• Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. Int J Clin Pharm 2013;35(6):1099-104
   Google Scholar
• Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000;109:307-14
   PubMed Web of Science ®Google Scholar
• Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995;98(6):575-86
   PubMed Web of Science ®Google Scholar
• Fenton F, Smally AJ, Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med 1996;28(4):440-1
   PubMed Web of Science ®Google Scholar
• Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ 2015;187(4):E138-43
   PubMed Web of Science ®Google Scholar
• Weir MA, Juurlink DN, Gomes T, et al. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. Clin J Am Soc Nephrol 2010;5(9):1544-51
   PubMed Web of Science ®Google Scholar
• Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney disease. J Am Geriatr Soc 2012;60:310-15
   PubMed Web of Science ®Google Scholar
• Drion I, Joosten H, Dikkeschei LD, et al. eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population. Eur J Intern Med 2009;20:722-7
   PubMed Web of Science ®Google Scholar
• Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009;20(1):164-71
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012;7(8):1234-41
   PubMed Web of Science ®Google Scholar
• Weinberg JM, Appel LJ, Bakris G, et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009;169(17):1587-94
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de ZD, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329(20):1456-62
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. the angiotensin-converting-enzyme inhibition in progressive renal insufficiency study Group. N Engl J Med 1996;334(15):939-45
   PubMed Web of Science ®Google Scholar
• Wright JTJr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421-31
   PubMed Web of Science ®Google Scholar
• Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 2012;30(3):e156-66
   PubMed Web of Science ®Google Scholar
• Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369(20):1892-903
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372(9638):547-53
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. N Engl J Med 2012;367(23):2204-13
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Ruilope LM. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int 2014;85(3):536-46
   PubMed Web of Science ®Google Scholar
• Buchner N, Banas B, Kramer BK. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008;359(4):426
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004;66(1):1-9
   PubMed Web of Science ®Google Scholar
• Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001;345(12):925-6
   PubMed Web of Science ®Google Scholar
• Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 2005;28(9):2106-12
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006;70(3):536-42
   PubMed Web of Science ®Google Scholar
• Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009;20(12):2641-50
   PubMed Web of Science ®Google Scholar
• Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008;51(2):199-211
   PubMed Web of Science ®Google Scholar
• Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009;30(5):418-24
   PubMed Web of Science ®Google Scholar
• Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012;81(10):955-68
   PubMed Web of Science ®Google Scholar
• Roscioni SS, de ZD, Bakker SJ, Lambers Heerspink HJ. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol 2012;8(12):691-9
   PubMed Web of Science ®Google Scholar
• Bakris G, Nowack C, Ruilope LM. Results of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes and diabetic nephropathy (Abstract). World Congress of Nephrology; CapeTown, South Africa: 2015
   Google Scholar
• K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(5 Suppl 2):1-290
   PubMed Web of Science ®Google Scholar
• Zannad F, Gattis SW, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012;33(22):2782-95
   PubMed Web of Science ®Google Scholar
• Keilani T, Danesh FR, Schlueter WA, et al. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 1999;33(3):450-7
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-17
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11-21
   PubMed Web of Science ®Google Scholar
• Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58(5):2084-92
   PubMed Web of Science ®Google Scholar
• Zipser RD, Henrich WL. Implications of nonsteroidal anti-inflammatory drug therapy. Am J Med 1986;80(1A):78-84
   Google Scholar
• Marinella MA. Trimethoprim-induced hyperkalemia: An analysis of reported cases. Gerontology 1999;45:209-12
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol 2014;39(2):171-82
   PubMed Web of Science ®Google Scholar
• Chan CY, Peterson EJ, Ng TM. Thiazide diuretics as chronic antihypertensive therapy in patients with severe renal disease--is there a role in the absence of diuresis? Ann Pharmacother 2012;46(11):1554-8
   PubMed Web of Science ®Google Scholar
• Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 2013;126(3):264-24
   PubMed Web of Science ®Google Scholar
• Watson MA, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am J Kidney Dis 2012;60(3):409-16
   PubMed Web of Science ®Google Scholar
• Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32(7):820-8
   PubMed Web of Science ®Google Scholar
• Packham DK, Rasmussen HS, Singh B. New agents for hyperkalemia. N Engl J Med 2015;372(16):1571-2
   PubMed Web of Science ®Google Scholar
• U.S. Renal Data System, USRDS 2013 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2014
   Google Scholar
• ADR. 2013. Available from: http://www.usrds.org/2013/view/v1_05.aspx [Last accessed 13 August 2015]
   Google Scholar